» Articles » PMID: 39455916

Dexmedetomidine Ameliorates Acute Kidney Injury by Regulating Mitochondrial Dynamics Via the α2-AR/SIRT1/PGC-1α Pathway Activation in Rats

Abstract

Background: Sepsis-associated acute kidney injury (AKI) is a serious complication of systemic infection with high morbidity and mortality in patients. However, no effective drugs are available for AKI treatment. Dexmedetomidine (DEX) is an alpha 2 adrenal receptor agonist with antioxidant and anti-apoptotic effects. This study aimed to investigate the therapeutic effects of DEX on sepsis-associated AKI and to elucidate the role of mitochondrial dynamics during this process.

Methods: A lipopolysaccharide (LPS)-induced AKI rat model and an NRK-52E cell model were used in the study. This study investigated the effects of DEX on sepsis-associated AKI and the molecular mechanisms using histologic assessment, biochemical analyses, ultrastructural observation, western blotting, immunofluorescence, immunohistochemistry, qRT-PCR, flow cytometry, and si-mRNA transfection.

Results: In rats, the results showed that administration of DEX protected kidney structure and function from LPS-induced septic AKI. In addition, we found that DEX upregulated the α2-AR/SIRT1/PGC-1α pathway, protected mitochondrial structure and function, and decreased oxidative stress and apoptosis compared to the LPS group. In NRK-52E cells, DEX regulated the mitochondrial dynamic balance by preventing intracellular Ca overloading and activating CaMKII.

Conclusions: DEX ameliorated septic AKI by reducing oxidative stress and apoptosis in addition to modulating mitochondrial dynamics via upregulation of the α2-AR/SIRT1/PGC-1α pathway. This is a confirmatory study about DEX pre-treatment to ameliorate septic AKI. Our research reveals a novel mechanistic molecular pathway by which DEX provides nephroprotection.

References
1.
Tao W, Shan X, Zhang J, Liu H, Wang B, Wei X . Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 α2-AR. Front Pharmacol. 2022; 13:782466. PMC: 9307125. DOI: 10.3389/fphar.2022.782466. View

2.
Feng X, Guan W, Zhao Y, Wang C, Song M, Yao Y . Dexmedetomidine ameliorates lipopolysaccharide-induced acute kidney injury in rats by inhibiting inflammation and oxidative stress via the GSK-3β/Nrf2 signaling pathway. J Cell Physiol. 2019; 234(10):18994-19009. DOI: 10.1002/jcp.28539. View

3.
Zarbock A, Gomez H, Kellum J . Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care. 2014; 20(6):588-95. PMC: 4495653. DOI: 10.1097/MCC.0000000000000153. View

4.
Patten I, Arany Z . PGC-1 coactivators in the cardiovascular system. Trends Endocrinol Metab. 2011; 23(2):90-7. DOI: 10.1016/j.tem.2011.09.007. View

5.
Loson O, Song Z, Chen H, Chan D . Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission. Mol Biol Cell. 2013; 24(5):659-67. PMC: 3583668. DOI: 10.1091/mbc.E12-10-0721. View